Tetanus and Pertussis vaccines: their usefulness in the aging population
- 80 Downloads
Immunization is a safe, effective and simple way of preventing life-threatening tetanus infection in children and adults, and is therefore recommended for all age groups in all European countries. In older persons, despite waning immunity with increasing age, the majority of vaccinees attain protective tetanus immunity under a proper vaccination schedule. Based on the scientific evidence, decennial boosters are recommended for elderly persons who have received primary tetanus vaccination in the past. Until recently, pertussis vaccination was understood as an early childhood intervention. Due to decreasing immunity, re-vaccination of youngsters and adults is recommended and is also considered for seniors 60 years and over. Routine immunization of seniors against pertussis every ten years yields a high level of protection of older individuals, and at the same time contributes to epidemiological control of pertussis in the population.
KeywordsAging pertussis vaccination tetanus vaccination
Unable to display preview. Download preview PDF.
- 2.Pascual FB, McGinley EL, Zanardi LR, Cortese MM, Murphy TV. Tetanus surveillance: United States, 1998–2000. Morb Mortal Wkly Rep Surveill Summ 2003; 52: 1–8.Google Scholar
- 5.Kretsinger K, Broder KR, Cortese MM et al; Centers for Disease Control and Prevention; Advisory Committee on Immunization Practices; Healthcare Infection Control Practices Advisory Committee. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acelter lular pertussis vaccine, recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep 2006; 55: 1–37.Google Scholar
- 16.CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006; 55 (No. RR-15).Google Scholar
- 18.Simonsen O, Badsberg JH, Kjeldsen K et al. The fall-off in serum concentration of tetanus antitoxin after primary and booster vaccination. Acta Pathol Microbiol Scand 1985; 94: 77–82.Google Scholar
- 20.Wassilak SGF, Roper MH, Kretsinger K, Orenstein WA. Tetanus toxoid. In Plotkin S, Orenstein W, Offit P, eds. Vaccines. 5th ed. Saunders Elsevier, 2008.Google Scholar
- 23.CDC. Percentage of persons aged ≥18 years who reported receiving influenza or pneumococcal vaccine or tetanus toxoid, by age and selected characteristics — National Health Interview Survey, United States, 1999. Available at http://www.cdc.gov/nip/coverage/NHIS/tables/general-99.pdf. Accessed February 28, 2009.
- 24.CDC. Record of the Meeting of the Advisory Committee on Immunization Practices, October 26–27, 2005. Available at http://www.cdc.gov/nip/ACIP/minutes/acip-min-oct05.pdf. Accessed February 28, 2009.
- 26.Bartošovič I, Krajčík Š, Hegyi L. Vaccination of social care facility residents agains influenza and tetanus (in Slovak). Geriatria 2001; 7: 164–8.Google Scholar
- 27.Edwards KM Decker MD. Pertussis vaccines. In Plotkin S, Orenstein W, Offit P, eds. Vaccines. 5th ed. Saunders Elsevier, 2008.Google Scholar
- 31.Quinn HE, McIntyre PB. Pertussis epidemiology in Australia over the decade 1995–2005 — trends by region and age group. Commun Dis Intell 2007; 31: 205–15.Google Scholar
- 35.CDC: Pertussis — United States, 2001–2003. Morb Mortal Wkly Rep 2005; 54: 1283–6.Google Scholar
- 36.Conference report: International Bordetella pertussis assay, standardization and harmonization meeting report. Center for Disease Control and Prevention, Atlanta, Georgia, United States, 19–20 July 2007. Vaccine 2009; 27: 803–14.Google Scholar
- 38.CDC. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine: recommendations of Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by healthcare personnel. Morb Mortal Wkly Rep 2006; 55: 1–3.Google Scholar
- 42.Rothstein E, Anderson E, Decker M, Poland G, Reisinger K, Langerberg A. An observer-blinded, randomised, placebo-controlled study of the safety and immunogenecity of an acellular pertussis vaccine (aP) in healthy adults (abstract G-29) In Abstracts of the 38th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC). ASM, Washington, 1998.Google Scholar